Abstract
Thirty-four patients with moderate-severe hirsutism were enrolled in this study. The patients received 125 mg/day flutamide for a period of 6 months. Hirsutism score and hormone parameters including FSH, LH, T, free T, androste-nedione (A), DHEAS, PRL and sex hormone-binding globulin (SHBG) levels were evaluated in all patients before treatment and repeated at every three-monthly intervals. Hirsutism greatly improved during flutamide therapy, and the hirsutism score significantly decreased at month 3 and 6 from a mean (±SD) of 17.19±4.55 to 10.75±3.84 (p<0.001) and 17.19±4.55 to 5.91±2.53 (p<0.001), respectively. A significant reduction in hirsutism score (mean%±SD) as compared to baseline was observed at 3 months (37.78±13.30, p<0.001) and at 6 months (65.47±13.49, p<0.001). No significant changes in the levels of hormone and no serious side effects were observed in the patients. The lower dose flutamide, 125 mg/day, is a safe and cost-effective drug in the treatment of hirsutism. Lower dose flutamide may be used in place of high dose flutamide, 250 to 750 mg/day.
Similar content being viewed by others
References
Krischner M.A., Bardin C.W. Androgen production and metabolism in normal and virilized women. Metabolism 21: 667, 1972.
Biffignandi P., Massuchetti C., Molinatti G.M. Female hirsutism: Pathophysiological considerations and therapeutic implications. Endocr. Rev. 5: 498, 1984.
Tremblay R.R. Treatment of hirsutism with spironolactone. J. Clin. Endocrinol. Metab. 5: 363, 1986.
Belisle L., Love E.J. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: Results of a multicentered Canadian study. Fertil. Steril. 46: 1015, 1986.
Dodin S., Faure N., Cedrin I., Mechain C., Turcot-Lemay L., Guy J., Lemay A. Clinical efficacy and safety of low-dose flutamide alone and combined with an oral contraceptive for the treatment of idiopathic hirsutism. Clin. Endocrinol. (Oxf.) 43: 575, 1995.
Neri R., Kassem N. Biological and clinical properties of antiandrogens. Progress in Cancer Research and Therapy 31: 507, 1984.
Moghetti P., Castello R., Negri C., Tosi F., Magnani C.M., Fontanarosa M.C., Armanini D., Muggeo M. Flutamide in the treatment of hirsutism: long-term clinical effects, endocrine changes, and androgen receptor behavior. Fertil. Steril. 64: 511, 1995.
Cesur V., Kamel N., Uysal A.Z., Erdoğan G., Başkal N. The use of antiandrogen flutamide in the treatment of hirsutism. Endocr. J. 41: 573, 1994.
Marcondes J.A.M., Minnani S.L., Luthold W.W., Bernardo L.W., Samojlik E., Kirschner M.A. Treatment of hirsutism in women with flutamide. Fertil. Steril. 57: 543, 1992.
Müderris I.I., Bayram F., Şahin Y., Keleştimur F., Tutuş A., Ayata D. The efficacy of 250 mg/day flutamide in the treatment of patients with hirsutism. Fertil. Steril. 66: 220, 1996.
Hatch R., Rosenfield R., Kim M.H., Tredway D. Hirsutism: implications, etiology, and managment. Am. J. Obstet. Gynecol. 140: 815, 1981.
Falsetti L., De Fusco D., Eleftheriou G., Rosina B. Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary sydrome. Gynecol. Endocrinol. 11: 251, 1997.
Erenus M., Gürbüz O., Durmuşoğlu F., Demirçay Z., Pekin S. Comparison of the efficacy of spironolactone versus flutamide in the treatment of hirsutism. Fertil. Steril. 61: 613, 1994.
Cusan L., Dupont A., Gomez J.-L., Tremblay R.R., Labrie F. Comparison of flutamide and spironolactone in the treatment of hirsutism: A randomized controlled trial. Fertil. Steril. 61: 28, 1994.
Moller S., Iversen P., Franzmann M.B. Flutamide-induced liver failure. J. Hepatol. 10: 346, 1990.
Wysdwski D.K., Freiman J.P., Tourtelot J.B., Horton M.L. Fatal and nonfatal hepatotoxicity associated with flutamide. Ann. Intern. Med. 118: 860, 1993.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Müderris, I.I., Bayram, F. Clinical efficacy of lower dose flutamide 125 mg/day in the treatment of hirsutism. J Endocrinol Invest 22, 165–168 (1999). https://doi.org/10.1007/BF03343536
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03343536